Abbott Laboratories (ABT)
Stock Price Chart
Key Info
| Market Cap | 183.16B |
| Revenue (ttm) | 31.44B |
| Net Income (ttm) | 3.11B |
| Shares Out | 1.77B |
| EPS (ttm) | 1.73 |
| PE Ratio | 59.80 |
| Forward PE | 23.15 |
| Dividend | $1.44 |
| Dividend Yield | 1.39% |
Stock Quote
| Trading Day | Sep 25, 2020 |
| Last Price | $103.45 |
| Previous Close | $100.92 |
| Change ($) | 2.53 |
| Change (%) | 2.51% |
| Day's Open | 100.48 |
| Day's Range | 100.34 - 103.61 |
| Day's Volume | 5,060,317 |
| 52-Week Range | 61.61 - 114.20 |
More Stats
| Market Cap | 183.16B |
| Enterprise Value | 197.80B |
| Earnings Date (est) | Oct 21, 2020 |
| Ex-Dividend Date | Jul 14, 2020 |
| Shares Outstanding | 1.77B |
| Float | 1.76B |
| EPS (basic) | 1.75 |
| EPS (diluted) | 1.73 |
| FCF / Share | 2.57 |
| Dividend | $1.44 |
| Dividend Yield | 1.39% |
| Earnings Yield | 1.67% |
| FCF Yield | 2.49% |
| Payout Ratio | n/a |
| Shares Short | 8.68M |
| Short Ratio | 1.32 |
| Short % of Float | 0.50% |
| Beta | 0.95 |
| PE Ratio | 59.80 |
| Forward PE | 23.15 |
| P/FCF Ratio | 40.13 |
| PS Ratio | 5.83 |
| PB Ratio | 5.84 |
| Revenue | 31.44B |
| Operating Income | 4.02B |
| Net Income | 3.11B |
| Free Cash Flow | 4.56B |
| Net Cash | -14.64B |
| Net Cash / Share | -8.27 |
| Gross Margin | 59.50% |
| Operating Margin | 12.78% |
| Profit Margin | 9.90% |
| FCF Margin | 14.51% |
| ROA | 4.01% |
| ROE | 9.86% |
| ROIC | 12.80% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31,904 | 30,578 | 27,390 | 20,853 | 20,405 | 20,247 | 19,657 | 19,050 | 21,407 | 35,167 |
| Revenue Growth | 4.34% | 11.64% | 31.35% | 2.2% | 0.78% | 3% | 3.19% | -11.01% | -39.13% | - |
| Gross Profit | 18,673 | 17,872 | 14,981 | 11,759 | 11,658 | 11,029 | 10,464 | 10,151 | 11,390 | 20,502 |
| Operating Income | 4,532 | 3,650 | 1,564 | 3,026 | 2,867 | 2,599 | 2,133 | 1,360 | 1,629 | 6,088 |
| Net Income | 3,687 | 2,368 | 477 | 1,400 | 4,423 | 2,284 | 2,576 | 5,963 | 4,728 | 4,626 |
| Shares Outstanding | 1,768 | 1,758 | 1,740 | 1,477 | 1,496 | 1,516 | 1,558 | 1,575 | 1,557 | 1,546 |
| Earnings Per Share | 2.06 | 1.33 | 0.27 | 0.94 | 2.92 | 1.49 | 1.62 | 3.72 | 3.01 | 2.96 |
| EPS Growth | 54.89% | 392.59% | -71.28% | -67.81% | 95.97% | -8.02% | -56.45% | 23.59% | 1.69% | - |
| Dividend Per Share | 1.28 | 1.12 | 1.06 | 1.04 | 0.96 | 0.88 | 35.21 | 2.01 | 1.88 | 1.72 |
| Dividend Growth | 14.29% | 5.66% | 1.92% | 8.33% | 9.09% | -97.5% | 1651.74% | 6.91% | 9.3% | - |
| Operating Cash Flow | 6,136 | 6,300 | 5,570 | 3,203 | 2,966 | 3,675 | 3,324 | 9,314 | 8,970 | 8,736 |
| Capital Expenditures | -1,638 | -1,394 | -1,135 | -1,121 | -1,110 | -1,077 | -1,145 | -1,795 | -1,491 | -1,015 |
| Free Cash Flow | 4,498 | 4,906 | 4,435 | 2,082 | 1,856 | 2,598 | 2,179 | 7,519 | 7,479 | 7,721 |
| Cash & Equivalents | 4,140 | 4,086 | 9,610 | 18,775 | 6,125 | 4,460 | 8,098 | 15,174 | 8,097 | 7,324 |
| Total Debt | 18,139 | 19,566 | 27,924 | 22,006 | 9,001 | 7,830 | 6,561 | 20,476 | 15,415 | 18,918 |
| Net Cash / Debt | -13,999 | -15,480 | -18,314 | -3,231 | -2,876 | -3,370 | 1,537 | -5,302 | -7,317 | -11,594 |
| Assets | 67,887 | 67,173 | 76,250 | 52,666 | 41,247 | 41,207 | 42,953 | 67,235 | 60,277 | 60,574 |
| Liabilities | 36,586 | 36,451 | 45,152 | 31,949 | 19,921 | 19,568 | 17,686 | 40,422 | 35,751 | 37,809 |
| Book Value | 31,301 | 30,722 | 31,098 | 20,717 | 21,326 | 21,639 | 25,267 | 26,813 | 24,526 | 22,765 |
Company Profile
Company Details
| Full Name | Abbott Laboratories |
| Country | United States |
| Employees | 107,000 |
| CEO | Robert B. Ford |
Stock Information
| Ticker Symbol | ABT |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NYSE: ABT |
Description
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.